LA BioMed Spinoff Announces Publishing of Phase 3 Trial Results from Sickle Cell Disease Drug

Results of Emmaus Life Science’s clinical trial published in The New England Journal of Medicine to grow worldwide awareness of debilitating disease

Putting an End to Deadly Antibiotic Resistance Caused by Over-Prescription

Successful Behavioral Interventions to Curb Over-Prescribing Found Cost Effective; LA BioMed Researcher’s New Study’s Results Have Life-Saving Implications.

Disease Screening in Newborns Given Boost from Federal Grant

NIH funded research led by Dr. Rie Sakai-Bizmark has potential to save the lives of hundreds of newborn babies annually

LA BioMed helps drive LA County's ranking as national Top-10 BioPharma Cluster

A new 78,000 SF research building and bioscience incubator are set to open in early 2019, further securing LA BioMed's contribution to biotech leadership in Southern California

Topping-Off Ceremony of 4-Story Research Building at LA BioMed Propels LA County’s 1st Biotech Hub

78,000 SF building to house new bioscience incubator on 11.5-acre campus that with Harbor- UCLA Medical Center and LA BioMed is on track to become the first biotech hub in the County

FDA approves new treatment for sickle cell disease

News provided by U.S. Food and Drug Administration

July 7, 2017

The U.S. Food and Drug Administration today approved Endari (L-glutamine oral powder) for patients age five years and older with sickle cell disease to reduce severe complications associated with the blood disorder.

LA BioMed Launches Commercialization Accelerator Program™ Powered by Larta Institute

Offers Additional Resources to Help its Startups Succeed

LOS ANGELES – (June 16, 2017) – LA BioMed is launching a Commercialization Accelerator Program™ (CAP), designed and implemented by Larta Institute, that will offer LA BioMed’s early stage bioscience companies additional resources to strengthen and speed their innovations to the marketplace, Keith B. Hoffman, PhD, LA BioMed vice president of business development and technology transfer, and Rohit Shukla,  Larta Institute CEO, announced today.